Jardimet XR Tablet 5 mg + 1000 mg is an extended-release fixed-dose combination of Empagliflozin and Metformin Hydrochloride, designed for the effective management of type 2 diabetes mellitus in adult patients. This formulation combines the proven benefits of two complementary antidiabetic agents in a convenient once-daily regimen, supporting sustained blood glucose control and improved treatment adherence.

Metformin Hydrochloride is a biguanide antidiabetic agent that works by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity in peripheral tissues. Empagliflozin belongs to the Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor class and lowers blood glucose by promoting urinary glucose excretion. The extended-release (XR) formulation of metformin ensures gradual drug release, helping maintain steady plasma levels and minimizing gastrointestinal side effects commonly associated with immediate-release metformin.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each extended-release tablet contains:

• Empagliflozin 5 mg

• Metformin Hydrochloride 1000 mg (Extended Release)

Therapeutic Class

• Antidiabetic Agents

• SGLT2 Inhibitor + Biguanide (Extended-Release Combination)

Indications and Uses

Jardimet XR Tablet 5 mg + 1000 mg is indicated for:

• Management of type 2 diabetes mellitus in adults

• Patients inadequately controlled with metformin monotherapy

• Adjunct to diet and lifestyle modifications to improve glycemic control

• Long-term diabetes treatment requiring higher-dose metformin with once-daily dosing

Mechanism of Action

Metformin XR lowers blood glucose by inhibiting hepatic gluconeogenesis, improving peripheral insulin sensitivity, and reducing intestinal glucose absorption. Empagliflozin selectively inhibits the SGLT2 transporter in the kidneys, reducing glucose reabsorption and increasing urinary glucose elimination. Together, they provide effective and insulin-independent glycemic control.

Key Benefits

• Dual-mechanism action for comprehensive blood glucose management

• Extended-release metformin for improved gastrointestinal tolerability

• Once-daily dosing enhances patient convenience and adherence

• Low risk of hypoglycemia when used appropriately

• Supports weight neutrality or modest weight reduction

Dosage and Administration

• Taken orally once daily, preferably with food

• Tablets should be swallowed whole; do not crush or chew

• Dosage should be individualized based on glycemic response and renal function

• Regular monitoring of blood glucose and kidney function is advised

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

• Use cautiously in patients with renal or hepatic impairment

• Ensure adequate hydration during therapy

• Rare risk of lactic acidosis associated with metformin

• Avoid excessive alcohol intake while on treatment

Adverse Effects

Common adverse effects may include nausea, diarrhea, abdominal discomfort, increased urination, urinary tract infections, and genital fungal infections. These effects are usually mild to moderate and tend to resolve with continued therapy.

Storage Conditions

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

Conclusion

Jardimet XR Tablet 5 mg + 1000 mg (Empagliflozin + Metformin Hydrochloride) offers an effective and convenient once-daily treatment option for adults with type 2 diabetes mellitus. With its extended-release formulation and dual glucose-lowering mechanisms, it supports sustained glycemic control and long-term diabetes management under medical supervision.